Precision fermentation is quietly becoming a supply chain strategy for biotech, not just a food tech story
Dr. Dereck Mush, MD, MBA
HexemBio
Synthetic yolk sac platform that rejuvenates aged blood stem cells for transplant.
What they do
HexemBio is a synthetic biology company whose Synthetic Human Yolk Sac microenvironment platform rejuvenates aged autologous hematopoietic stem cells for bone marrow transplantation. The company has raised $15.5M from investors including Draper Associates, Boost VC and Happiness Capital.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Synthetic biology
- Product type
- Platform software
- Stage
- Seed
- Headquarters
- San Francisco, CA
- Region
- North America
- Founded
- Not disclosed
- Total funding
- $16M raised
Notable investors: Draper Associates, Boost VC, Happiness Capital.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
Closing the Assay Loop: Inside Anthropic's $400M Wet Lab Pivot
Dr. Dereck Mush, MD, MBA
AI is moving upstream, from molecule design into disease target identification itself
Dr. Dereck Mush, MD, MBA
The End of Phase-Gated Trials: How ARPA-H's SURPASS Program Reengineers Biomedical R&D
Dr. Dereck Mush, MD, MBA